Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
Rhea-AI Summary
Femasys Inc. (FEMY), a biomedical company focusing on women's health, announces its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024 at the Lotte New York Palace Hotel. Kathy Lee-Sepsick, Founder, President, and CEO of Femasys, will engage in a fireside chat hosted by Emily Bodnar, Life Sciences Analyst.
The presentation will be available on-demand starting September 9, 2024, at 7:00 AM ET. Investors can access the webcast through the provided link or the investor relations section of the Femasys website. The replay will be available for approximately 90 days after the event. Additionally, Kathy Lee-Sepsick and CFO Dov Elefant will be available for one-on-one meetings throughout the conference.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, FEMY declined 6.84%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
ATLANTA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that Kathy Lee-Sepsick, Founder, President, and CEO, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference. The fireside chat will be hosted by Emily Bodnar, Life Sciences Analyst. The conference is being held on September 9 – 11, 2024 at the Lotte New York Palace Hotel.
| Presentation Date: | September 9, 2024 |
| Time: | Available on-demand starting at 7:00 AM ET |
| Webcast Link: | |
| https://journey.ct.events/view/40d58b25-f692-4267-996d-eb0cf50146ec | |
A webcast of the presentation can be accessed on the investor relations section of the Femasys website. A replay of the webcast will be archived and available following the event for approximately 90 days.
https://ir.femasys.com/events-and-presentations/default.aspx
Kathy Lee-Sepsick and Dov Elefant, Chief Financial Officer, will be available for one-on-one meetings throughout the conference. To request a meeting and to register for the conference, click below:
https://hcwevents.com/annualconference/
About Femasys
Femasys is a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions, including a lead revolutionary product candidate and FDA-cleared products. FemaSeed® Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is FDA-cleared and has received regulatory approval in Canada and Europe. FemBloc® permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada, Europe, and other ex-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. Its diagnostic products include FemVue® and FemVue® Mini for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath®, an intrauterine catheter for selective fallopian tube evaluation, and FemCerv®, an endocervical tissue sampler for cervical cancer diagnosis. Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; estimates regarding the total addressable market for our products and product candidates; our ability to commercialize our products and product candidates, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
Investors:
CORE IR
Matt Blaise
IR@femasys.com
Media:
CORE IR
Kati Waldenburg
Media@femasys.com
FAQ
When is Femasys (FEMY) participating in the H.C. Wainwright Global Investment Conference?
Who will represent Femasys (FEMY) at the H.C. Wainwright conference?
Where can investors access the Femasys (FEMY) presentation from the H.C. Wainwright conference?
What is the focus of Femasys (FEMY) as a company?
